Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04315558 · ClinicalTrials.gov registry record · Phase 2
Revefenacin in Acute Respiratory Insufficiency in COPD
A Phase 2 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT04315558 is a Phase 2 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 21 participants.
The verdict
NCT04315558, a Phase 2 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.
Interventions
- DRUG Ipratropium Bromide
- DRUG Revefenacin Inhalation Solution [Yupelri]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2025-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04315558
The ClinicalTrials.gov registry entry for NCT04315558 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipratropium Bromide is the first listed.
NCT04315558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04315558 about?
NCT04315558 is a clinical study titled "Revefenacin in Acute Respiratory Insufficiency in COPD". RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.
What is the current status of trial NCT04315558?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2020-11-01. Estimated completion is 2025-01-01.
What interventions are being tested in trial NCT04315558?
The interventions under investigation include: Ipratropium Bromide (DRUG), Revefenacin Inhalation Solution [Yupelri] (DRUG).
Who is sponsoring clinical trial NCT04315558?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.